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High-resolution crystal structure 
of the therapeutic antibody 
pembrolizumab bound to the 
human PD-1
Shoichiro Horita1, Yayoi Nomura1,2, Yumi Sato1,2, Tatsuro Shimamura1,2, So Iwata1,2,3 & 
Norimichi Nomura1,2
Pembrolizumab is an FDA-approved therapeutic antibody that targets the programmed cell death-1 
(PD-1) to block the immune checkpoint pathway for the treatment of various types of cancer. It receives 
remarkable attention due to the high degree of efficacy. Very recently, the crystal structure of the Fab 
fragment of pembrolizumab (PemFab) in complex with the extracellular domain of human PD-1 (PD-1ECD) 
was reported at a resolution of 2.9 Å. However, this relatively low-resolution structural data fails to provide 
sufficient information on interfacial water molecules at the binding interface that substantially contribute 
to affinity and specificity between the therapeutic antibody and target. Here, we present the independently 
determined crystal structure of the Fv fragment of pembrolizumab (PemFv) in complex with the PD-1ECD 
at a resolution of 2.15 Å. This high-resolution structure allows the accurate mapping of the interaction 
including water-mediated hydrogen bonds and provides, for the first time, a coherent explanation of PD-1 
antagonism by pembrolizumab. Our structural data also provides new insights into the rational design of 
improved anti-PD-1 therapeutics.
When the PD-1 (also known as CD279) inhibitory receptor binds its endogenous ligand, PD-L1 (CD274, B7-H1), 
the resulting signalling suppresses immune responses against autoantigens and plays an important role in the 
maintenance of peripheral immune tolerance1. However, a significantly increased expression of PD-L1 in var-
ious tumours permits these malignant cells to escape destruction by the immune system2,3. The PD-1/PD-L1 
interaction inhibits T-lymphocyte proliferation, release of cytokines, and cytotoxicity, resulting in exhaustion of 
tumour-specific T cells4. The blockage of the PD-1/PD-L1 pathway results in the reversal of the exhausted T-cell 
phenotype and the normalization of the anti-tumour response, providing a rationale for cancer immunotherapy5.
Targeting the PD-1/PD-L1 interaction with monoclonal antibodies has demonstrated great promise as a strat-
egy for controlling and eradicating cancer. Two antibodies against PD-1, pembrolizumab (Keytruda, Merck and 
Co.) and nivolumab (Opdivo, Bristol-Myers Squibb), were approved by the U.S. Food and Drug Administration 
(FDA) in 2014 for patients with advanced melanoma6,7. Recent clinical trials have shown that these antibod-
ies are effective against other cancers, such as non-small cell lung cancer, renal cell carcinoma, bladder cancer, 
and Hodgkin’s lymphoma8. It is widely expected that anti-PD-1 antibodies are likely to become an important 
component of treatment for a variety of malignancies. Although these antibodies are associated with substantial 
benefits, the immune checkpoint blockade can lead to inflammatory side effects9. Obtaining the atomic struc-
ture of the human PD-1/therapeutic antibody complex is essential for understanding its inhibition mechanism 
and the design of improved anti-PD-1 therapeutics. Very recently, the crystal structure of the Fab fragment of 
pembrolizumab in complex with the extracellular domain of human PD-1 (PD-1ECD) has been determined at 
a resolution of 2.9 Å10. Although the binding site of pembrolizumab on PD-1 has been roughly identified, this 
relatively low-resolution structural data does not provide sufficient information on interfacial water molecules at 
the binding interface that substantially contribute to affinity and specificity between the receptor and therapeutic 
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antibody. To provide a sufficient rationale for PD-1 antagonism by pembrolizumab, it is necessary to visualize 
water-mediated hydrogen bonds with higher-resolution structural data.
Herein, we present the independently determined crystal structure of the Fv fragment of pembrolizumab 
(PemFv) in complex with PD-1ECD at a resolution of 2.15 Å and compare its intermolecular interface with that of 
the PD-L1/PD-1ECD complex including water-mediated hydrogen bond networks. Our high-resolution structural 
data provides a coherent explanation of the mode of competitive inhibitory action by pembrolizumab. Moreover, 
it provides new insights into the rational design of improved anti-PD-1 therapeutics.
Results and Discussion
Structure of pembrolizumab Fv in complex with PD-1. Considering that both PemFv and PD-1ECD 
contain intrachain disulfide bonds, a Gram-positive bacterial secretion expression system was used to produce 
these proteins for crystallography (Methods). The resulting co-crystals appeared in the space group P212121, and 
the structure was determined by molecular replacement to a resolution of 2.15 Å (Rwork and Rfree values of 18.4% 
and 22.6%, respectively)(Table 1 and Supplementary Figure S1). Although each asymmetric unit of the crystals 
contains four complex assemblies, analytical gel filtration confirmed that the 1:1 complex (approximately 42 kDa) 
exists as a monomer in solution (data not shown).
The overall structure of the PemFv/PD-1ECD complex shows that the complementarity determining regions 
(CDRs) of PemFv interact predominantly with a major groove in PD-1ECD, which is formed on one surface by the 
CC’FG antiparallel β − sheet and the BC, C’D, and FG loops (Fig. 1a). The interface includes 15 direct hydrogen 
bonds between residues, 15 water-mediated hydrogen bonds, two salt bridges, and hydrophobic interactions, and 
a total of 26 residues of PD-1ECD are involved in the interaction (Fig. 2). The complex formation buries a very large 
solvent-accessible surface area of 1,137 Å2 on PD-1ECD, which is much higher than the common value observed 
in other antigen/antibody complexes11. Most prominently, residues located in loop C’D (Pro84 to Gly90) and in 
strand C’ (Gln75 to Lys78) of PD-1ECD provide a key part of the interactions, mainly through hydrogen bonds 
and salt bridges to the CDR-L3, CDR-H1, CDR-H2 and CDR-H3 of pembrolizumab. The N-linked glycosylated 
residues Asn49, Asn58, Asn74 and Asn116 are located away from the interface, suggesting that the sugar chains 
have no direct contact with pembrolizumab.
Less surprisingly, the overall structure of the PemFv/PD-1ECD complex reported here was similar to that of the 
PemFab/PD-1ECD complex (PDB ID: 5JXE)10. Both structure’s backbones align very well with a root-mean-square 
deviation (r.m.s.d.) of 0.38 Å (with 192 Cα atoms). Nevertheless, one important novelty of our study is the visuali-
zation of 15 water-mediated hydrogen bonds at the binding interface (Fig. 2, green lines). The previously reported 
PemFab/PD-1ECD complex structure only visualizes 8 direct hydrogen bonds and one salt bridge. Because of 
its relatively low resolution of 2.9 Å, there is no assignment of hydrogen-bonded interfacial water molecules 
Protein name PemFv/PD-1ECD
X-ray data collection
 Source, wavelength SPring-8 BL41XU, 1.00000 Å
 Resolution (Å)a 45.4–2.15 (2.20-2.15)
 Space group P212121
 Unit cell parameter (Å) a 143.7, b 143.1, c 76.6
 Unique reflectionsa 86668 (4231)
 Redundancya 6.5 (6.5)
 Completenessa 99.6 (98.3)
 Rmerge (%)a 9.4 (111.2)
 CC1/2 (%)a 99.9 (54.2)
 < I/σ (I)> a 15.5 (1.5)
Refinement
 Resolution (Å)a 45.4–2.15 (2.18-2.15)
 Rwork/Rfree (%)a,b 18.4/22.6 (30.7/34.5)
 R.m.s. deviations
 Bonds (Å) 0.004
 Angles (°) 0.730
 No. of atoms (average B-factors (Å2))
 PD-1 3519 (54.2)
 Pembrolizumab 7072 (43.1)
 Water 271 (46.1)
Ramachandran plot
 Favored region (%) 97.7
 Allowed region (%) 2.3
Table 1.  Crystallographic data collection and refinement statistics. aValues for the highest resolution shells 
are shown in parentheses. bRwork was calculated with 95% of the unique reflections used for refinement, whereas 
Rfree was calculated with the remaining 5% of the unique reflections.
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that mediate imperfect surface complementarity of the antibody/antigen interface (Supplementary Figure S2). 
Without considering the structural and energetic contribution of the interfacial water molecules, one cannot 
provide a sufficient rationale for the extremely high binding affinity of pembrolizumab against PD-1.
Comparison of binding sites of PD-1 for pembrolizumab and PD-L1. It has been shown that the 
intermolecular interaction between PD-1 and PD-L1 occurs mainly via the CC’FG sheet within both proteins12,13. 
In the crystal structure of human PD-1ECD in complex with the N-terminal half of the extracellular domain of 
human PD-L1 (PD-L1ECD-N) (PDB ID: 4ZQK)13, there is a hydrophobic surface patch formed by residues Val64, 
Tyr68, Ile126, Leu128, Ala132 and Ile134 in PD-1ECD that interacts with PD-L1ECD-N. Surrounding the hydropho-
bic patch, several hydrophilic residues of PD-L1ECD-N interact with residues Asn66, Tyr68, Gln75, Thr76, Asp77, 
Lys78, Ala132 and Glu136 of PD-1ECD, forming numerous hydrogen bonds and salt bridges (Fig. 1b and Fig. 2). 
In total, 12 residues of PD-1ECD participate in its interactions with PD-L1ECD-N, forming 9 direct hydrogen bonds 
between residues, three water-mediated hydrogen bonds, two salt bridges and hydrophobic interactions. The 
interface buries 796 Å2 of the solvent-accessible surface area on PD-1ECD.
A structural comparison between the PemFv/PD-1ECD complex and the PD-L1ECD-N/PD-1ECD complex 
indicates that the epitope recognized by pembrolizumab overlaps largely with the residues in PD-1 responsi-
ble for the interaction with PD-L1. Seven residues (Asn66, Gln75, Thr76, Asp77, Lys78, Ala132 and Glu136) 
of PD-1ECD participate in polar interactions with both PemFv and PD-L1ECD-N, and a solvent-accessible surface 
area of 682 Å2 on PD-1ECD is commonly buried in the complex with either PemFv or PD-L1ECD-N (Fig. 1c and 
Fig. 2). The disparity of binding affinities (a KD value of 8.2 μ M for PD-1ECD/PD-L1ECD-N14, versus a KD value of 
Figure 1. Structure of the pembrolizumab/PD-1 complex and comparison with the PD-L1/PD-1 complex. 
(a) Overall structures of the PemFv/human PD-1ECD complex (this study; left) and the human PD-L1ECD-N/
human PD-1ECD complex (PDB ID: 4ZQK; right). PD-1ECD, PemFv and PD-L1ECD-N are shown in light pink 
(surface representation), blue (ribbon diagram) and green (ribbon diagram), respectively. Canonical designations 
of β strands within PD-1ECD are also shown. (b) Close-up views of interfaces. Residues involved in hydrogen 
bonds (blue dashes) are shown. The color-coding is the same as in (a). A water molecule is shown in red. (c) Steric 
overlap on the PD-1 surface that interact with pembrolizumab and PD-L1. The pembrolizumab epitope (outlined 
in light blue) overlaps with the binding regions for PD-L1 (outlined in light green). PD-1ECD is represented by 
a grey surface and rotated by 180° around the vertical axis. The binding regions and the overlapping areas are 
coloured and marked differently.
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27 pM for PD-1ECD/pembrolizumab IgG15) can be attributed to a significant difference in the number of polar 
interactions, including water-mediated hydrogen bonds. These observations rationalize that the binding of pem-
brolizumab to PD-1 would compete with the binding of PD-L1 to the receptor. In the absence of pembrolizumab, 
the binding of the inactive PD-1 receptor to the PD-L1 dimer16 would trigger receptor dimerization, followed 
by the trans-phosphorylation of a tyrosine within the immunoreceptor tyrosine-based switch motif (ITSM), the 
recruitment of the protein tyrosine phosphatase SHP-2, and the dephosphorylation of the T-cell receptor (TCR) 
proximal signalling molecules including ZAP70, PKCθ, and CD3ζ. This would lead to the attenuation of the TCR 
signal to suppress the immune response17. However, in the presence of a sufficient amount of pembrolizumab, 
the PD-L1 binding site on PD-1 would be blocked, and thus, PD-1 would not be able to undergo dimerization. 
Therefore, the PD-1 signalling would not be performed.
Implications for development of improved anti-PD-1 drugs. Pembrolizumab forms a large, flat para-
tope to accommodate a large conformational epitope on PD-1. Upon the binding of pembrolizumab, PD-1ECD 
undergoes a peripheral conformational change, probably because of an induced fit, to generate a “crescent”-like 
structure with a shallow concave groove; this differs from the flat surfaces of the apo- and PD-L1-bound forms 
of PD-1ECD (Fig. 3). However, the groove is too shallow to design traditional small-molecule drugs that can bind 
tightly to prevent the binding of PD-L1.
Instead, the structural data reported here is a useful resource for the rational design of middle-sized molecules 
such as cyclic peptides or DNA and RNA aptamers that may possibly more easily mimic the effect of the binding 
of pembrolizumab to PD-1. For instance, on the basis of the structural data of the PemFv/PD-1ECD complex, the 
Rosetta Peptiderive program18 identified that a 13-residue linear polypeptide segment spanning from HAla97 to 
HTyr109 of PemFv contributes most predominantly to the complex binding energy (Fig. 4a). A cyclic peptide 
derivative of this “hot segment” (Cys-Ala-Arg-Arg-Asp-Tyr-Arg-Phe-Asp-Met-Gly-Phe-Asp-Tyr-Trp-Gly-Cys; 
a peptide structurally constrained by a disulfide bond between the terminal Cys residues) was designed, and the 
complex formation with PD-1ECD was modelled (Fig. 4b). In this model, the binding site of the cyclic peptido-
mimetic is overlapped with that of PD-L1. The PRODIGY program19 estimated that a KD value of the binding 
affinity of the cyclic peptide to PD-1ECD is 5.6 × 10−7 M. This cyclic peptide would be a good starting material for 
the development of downsized blockers of the PD-1/PD-L1 pathway. Structure-guided design of such peptidomi-
metics could overcome disadvantages of the current therapeutic antibody associated with the extremely high cost 
of commercial-scale production and the limited penetration into tissues.
Our high-resolution structural data of the PemFv/PD-1ECD complex also serves as a guide for further engi-
neering of pembrolizumab to strike a balance between its efficacy and reducing its adverse effects. Different com-
binations of targeted disruption of the direct or water-mediated hydrogen bonds and the salt bridges observed 
at the binding interface should modulate the affinity of pembrolizumab against PD-1. Such structure-guided 
mutagenesis can generate derivatives with lower affinities for PD-1, resulting in a shift of the binding equilibrium 
Figure 2. A schematic diagram of polar interactions. Direct protein/protein hydrogen bonds are in blue; 
water-mediated hydrogen bonds are in green; and salt bridges are in red.
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towards partially active (PD-L1-bound) states of PD-1. Creating partially inverse agonist antibodies would have 
novel implications for immune cell signalling and its regulation.
In summary, we report the high-resolution structure of pembrolizumab Fv in complex with the human PD-1 
extracellular domain, which enables us to identify the detailed intermolecular interface between pembrolizumab 
and PD-1. This structure allows for a deep understanding and mechanistic interpretation of PD-1 immune block-
ade therapy by pembrolizumab. It also provides a good starting point for facilitating efforts to develop improved 
anti-PD-1 therapeutics to modulate immune responses to fight cancer.
Figure 3. Conformational changes of PD-1 upon binding of pembrolizumab or PD-L1. (a) The r.m.s.d. 
for Cα atoms between the pair of PD-1ECD in apo-form and PemFv-bound form (upper panel), and between 
the pair of PD-1ECD in apo-form and PD-L1-bound form (lower panel). The secondary structural features of 
PD-1ECD are depicted at the bottom. Boxes in a dotted line highlight loops experiencing major conformational 
changes. n.d.: not determined. (b) Superposition of PD-1ECD molecules. PD-1ECD in apo- and PemFv-bound 
form (left), and PD-1ECD in apo- and PD-L1ECD-N-bound form (right). Orange arrows represent interfaces with 
which PemFv and PD-L1ECD-N interact.
www.nature.com/scientificreports/
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Methods
Complete amino-acid sequence of the expression constructs. The cloned Homo sapiens PD-1 
sequence contains residues 32 to 160 from the complete 288 residues (UniProt accession number: Q15116); The 
C93S mutation is underlined, and additional N- and C-terminal residues retained after restriction site cloning or 
TEV cleavage are shown in italics (refer to the following section for cloning details):
G S WN PP TF SP AL LV VT EG DN AT FT CS FS NT SE SF VL NW YR MS PS NQ TD KL AA FP ED RS QP GQ D S RF RV TQ-
LP NG RD FH MS VV RA RR ND SG TY LCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPTSENLYFQ.
The pembrolizumab light chain variable region (PemVL); the additional C-terminal residues that were 
retained after TEV cleavage are shown in i ta li cs:
E IV LT QS PA TL SL SP GE RA TL SC RA SK GV ST SG YS YL HW YQ QK PG QA PR LL IY LA SY LE SG VP AR FS GS GS GT-
DF TL TI SS LEPEDFAVYYCQHSRDLPLTFGGGTKVEIKTSENLYFQ.
The pembrolizumab heavy chain variable region ( Pe mV H ):
Q VQ LVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNR
VTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS.
Protein expression and purification. The PD-1 extracellular domain (PD-1ECD) and pembrolizumab Fv 
(PemFv) were expressed in Brevibacillus choshinensis and secreted as His6-tagged proteins. The proteins were 
purified from culture medium. The artificially synthesized codon-optimized cDNA of PD-1ECD, PemVL and 
PemVH were inserted downstream of and in frame with the secretion signal sequence of the plasmid pNY326 
(Clontech), which contains a neomycin-resistance gene and the constitutively active promoter P5. To facilitate the 
detection and purification of the secreted proteins, the sequences for the tobacco etch virus (TEV) protease cleav-
age site and a His6 tag were placed at the C-termini of the PD-1ECD and PemVL cDNAs. All cloned inserts were 
verified by sequencing of both strands. Non-sporulating Brevibacillus choshinensis HPD31-SP3 cells (Clontech) 
were electroporated with the individual plasmids under the conditions of 7.5 kV/cm, 25 μ F, and 1000 Ω according 
to the manufacturer’s instructions. The cells were grown at 30 °C and 200 rpm in 2SY medium (soypton 40 g/L, 
yeast extract 5 g/L, glucose 20 g/L, and CalCl2 0.15 g/L) supplemented with 50 mg/L neomycin. For the expression 
of PemFv, the cells expressing PemVL and PemVH were initially grown separately as overnight precultures. The 
precultures were then combined, diluted in 2SY medium to give an OD600 of 0.02 for each strain, and grown for 
65–70 h. The cells were removed by centrifugation at 6,000 g for 15 min. The recovered culture supernatant was 
adjusted to a final ammonium sulfate concentration of 60% saturation. The precipitate was pelleted, dissolved in 
TBS buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl), and dialyzed overnight against the same buffer. The dia-
lyzed sample was mixed with Ni-NTA resin equilibrated with buffer A (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
and 20 mM imidazole). Bound proteins were eluted with buffer B (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 
250 mM imidazole), mixed with TEV-His6 and dialyzed overnight against TBS buffer. The cleaved His6 tag and 
TEV-His6 were removed using a HisTrap column equilibrated with buffer A. Tag-free Fv fragments were concen-
trated and loaded onto a HiLoad 16/60 Superdex 75 column (GE Healthcare) equilibrated with TBS buffer. The 
peak fractions were pooled, concentrated, flash frozen in liquid nitrogen, and stored at − 80 °C.
Crystallisation. The protein complex was prepared by incubating PD-1ECD with PemFv at a molar ratio of 1:2 
for 1 h on ice. The complex was subjected to size exclusion chromatography (Superdex 200 10/300 column, GE 
Figure 4. Structure-based identification of “hot segments” in the pembrolizumab-PD-1 interaction and 
design of a putative cyclic peptide binder. (a) An output of Peptiderive program18. Intermolecular binding 
energies between PD-1ECD and all overlapping 13-mer peptide segments derived from the two variable domains 
(VL and VH) of pembrolizumab were calculated on the basis of the structural data of the PemFv/PD-1ECD 
complex, as reported in REU (Rosetta energy units). The horizontal axis indicates the starting residue of each 
sliding window consisting of a 13-mer peptide segment. (b) A structural model of the complex of PD-1ECD 
(surface) and a cyclic peptide (stick representation) with a favourable binding energy. The residues of PD-1ECD 
that are involved in the interactions with both pembrolizumab and PD-L1 are coloured in red. Canonical 
designations of β strands are also shown.
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Healthcare). Peak fractions containing the PD-1ECD/PemFv complex were concentrated to approximately 10 mg/
mL by ultrafiltration (Millipore, MWCO 10 kDa) and used for the crystallisation experiments. The crystals of the 
complex used for structural determination were grown at 20 °C by sitting drop vapor diffusion. A 50-μ L reservoir 
containing 20% PEG 3350 and 0.2 M KNO3 was equilibrated against a 0.4 μ L drop containing a 1:1 mixture of the 
complex and reservoir solution. After 20 days of growth, the crystals were cryo-protected in 25% ethylene glycol 
in the mother liquor and then flash-frozen in liquid nitrogen.
Data collection, structure determination and analysis. The diffraction data were collected at 100 K 
at the SPring-8 beamline BL41XU (Japan) using a PILATUS3 6M detector. The data were then integrated and 
scaled using XDS20. The structure of the PD-1ECD/PemFv complex was determined by molecular replacement 
with the program MR-PHASER21 using the atomic coordinates of the extracellular domain of human PD-1 (PDB 
ID: 3RRQ) and the Fv portion of pembrolizumab (PDB ID: 5DK3)22 as the search models. The model was further 
rebuilt in COOT23 and refined with phenix.refine24 (Table 1). The obtained crystals were merohedrally twinned 
according to phenix.xtriage24 and the data were refined with twin law (k, h, -l). Also, it should be noted that the 
data were processed with orthorhombic crystal system instead of tetragonal (despite of a- and b- axes with nearly 
the same length) based on refinement statistics. In the final Ramachandran plot, 97.7% and 2.3% of residues were 
in the favored and allowed regions, respectively. The refined structures were visualized with PyMOL (http://
www.pymol.org/). The PISA server25 was used for identifying protein-protein interactions and estimating the 
solvent-accessible surface area. The Peptiderive server18 (http://rosie.rosettacommons.org/peptiderive) was used 
to identify hot segments of the PemFv/PD-1ECD interaction. The hot segments are linear peptide stretch with 
significant binding energy compared to that of the whole protein-protein interaction. The program was run with 
setting the peptide lengths to derive as 5 to 20, separately. The PRODIGY server19 (http://milou.science.uu.nl/
services/PRODIGY) was used to estimate the binding affinity of the complexes of peptidemimetics/PD-1ECD on 
the basis of their structural models.
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